AccScience Publishing / ITPS / Volume 7 / Issue 2 / DOI: 10.36922/itps.2019
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

Therapeutic small molecules in the development of treatment for subarachnoid hemorrhage

Siddharth Shah1* Abiy Tereda2 Brandon Lucke-Wold1 Pavel S. Pichardo-Rojas3
Show Less
1 Department of Neurosurgery, University of Florida, Gainesville, Florida, USA
2 Department of Neurosurgery, Georgetown American University, George Town, Guyana
3 The Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA
INNOSC Theranostics and Pharmacological Sciences 2024, 7(2), 2019
Submitted: 12 October 2023 | Accepted: 7 November 2023 | Published: 11 January 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( )

Subarachnoid hemorrhage (SAH) is a severe and often fatal condition characterized by the accumulation of blood beneath the arachnoid layer of the meninges. Predominantly affecting individuals in the 40–60 age range, it is commonly caused by head trauma from falls or car accidents. Ruptures of cerebral aneurysms also contribute significantly to SAH. Risk factors for SAH include hypertension and smoking, and symptoms typically include severe headache and neck pain. Diagnosing SAH typically involves a combination of medical history, physical examination, and imaging studies such as computed tomography angiography or magnetic resonance imaging angiography. Recent research suggests that pharmaceutical management of intracerebral hemorrhage (ICH) includes the administration of recombinant activated factor VII, tranexamic acid, and aggressive blood pressure reduction. For patients with significant SAH and ICH, minimally invasive surgical procedures for hematoma evacuation, as well as surgical evacuation of SAH and ICH, have proven to be highly beneficial. Furthermore, an emerging area of treatment involves therapeutic small molecules designed to interrupt the pathophysiological pathways leading to SAH. This novel approach holds promise for advancing our understanding and management of this complex medical condition.

Subarachnoid hemorrhage
Therapeutic small molecules
Novel therapy
Pharmacological management
  1. Lai PMR, Du R, 2016, Association between s100b levels and long-term outcome after aneurysmal subarachnoid hemorrhage: Systematic review and pooled analysis. PLoS One, 11: e0151853.


  1. Su XW, Chan AHY, Lu G, et al., 2015, Circulating microrna 132-3p and 324-3p profiles in patients after acute aneurysmal subarachnoid hemorrhage. PLoS One, 10: e0144724.


  1. Ziu E, Khan Suheb MZ, Mesfin FB, 2023, Subarachnoid hemorrhage. In: StatPearls. Treasure Island, FL: StatPearls Publishing. Available from: books/NBK441958 [Last accessed on 2023 Jun 01].


  1. Grandhi R, Kottenmeier E, Cameron HL, et al., 2021, Influence of neurovascular embolic coil primary wind diameter on aneurysm packing density and case costs. J Med Econ, 24: 345–351.


  1. Hwong WY, Ang SH, Bots ML, et al., 2021, Trends of stroke incidence and 28-day all-cause mortality after a stroke in Malaysia: A linkage of national data sources. Glob Heart, 16: 39.


  1. Cai YY, Zhuang YK, Wang WJ, et al., 2022, Potential role of serum hypoxia-inducible factor 1alpha as a biomarker of delayed cerebral ischemia and poor clinical outcome after human aneurysmal subarachnoid hemorrhage: A prospective, longitudinal, multicenter, and observational study. Front Neurol, 13: 1072351.


  1. Koseki H, Aoki T, 2016, Population of inflammatory cells in intracranial aneurysm with the special insight to the development of novel diagnostic and therapeutic approaches. Neuroimmunol Neuroinflamm, 3: 173.


  1. Xing L, Long H, Bo R, et al., 2022, A computational model of blood d-dimer, cystatin c, and CRP levels predicts the risk of intracranial aneurysms and their rupture. Computat Intell Neurosci, 2022: 2216509.


  1. Cikla U, Aagaard-Kienitz B, Turski PA, et al., 2014, Familial perimesencephalic subarachnoid hemorrhage: Two case reports. J Med Case Rep, 8: 380.


  1. van Gijn J, Kerr RS, Rinkel GJ, 2007, Subarachnoid haemorrhage. Lancet, 369: 306–318.


  1. Bonita R, Thomson S, 1985, Subarachnoid hemorrhage: Epidemiology, diagnosis, management, and outcome. Stroke, 16: 591–594.


  1. Claassen J, Park S, 2022, Spontaneous subarachnoid haemorrhage. Lancet, 400: 846–862.


  1. Ronchetti G, Morales-Valero SF, Lanzino G, et al., 2015, A cause of atypical intracranial subarachnoid hemorrhage: Posterior spinal artery aneurysms. Neurocrit Care, 22: 299–305.


  1. Olsen MH, Lilja-Cyron A, Bache S, et al., 2019, Aneurismal subaraknoidalblødning. Ugeskr Laeger, 181: V01190019.


  1. Macdonald RL, Schweizer TA, 2017, Spontaneous subarachnoid haemorrhage. Lancet, 389: 655–666.


  1. Al-Shahi R, White PM, Davenport RJ, et al., 2006, Subarachnoid haemorrhage. BMJ, 333: 235–240.


  1. Hutton CF, 1954, Subarachnoid haemorrhage. Br J Radiol, 27: 471–472.


  1. Richardson A, 1969, Subarachnoid haemorrhage. Br Med J, 4: 89–92.


  1. Jolobe OM, 2007, Subarachnoid haemorrhage. Lancet, 369: 904.


  1. Long B, Koyfman A, Runyon MS, 2017, Subarachnoid hemorrhage: Updates in diagnosis and management. Emerg Med Clin North Am, 35: 803–824.


  1. Vivancos J, Gilo F, Frutos R, et al., 2014, Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment. Neurologia, 29: 353–370.


  1. Moore SA, Rabinstein AA, Stewart MW, et al., 2014, Recognizing the signs and symptoms of aneurysmal subarachnoid hemorrhage. Expert Rev Neurother, 14: 757–768.


  1. Larson AS, Brinjikji W, 2021, Subarachnoid hemorrhage of unknown cause: Distribution and role of imaging. Neuroimaging Clin North Am, 31: 167–175.


  1. Edlow JA, 2005, Diagnosis of subarachnoid hemorrhage. Neurocrit Care, 2: 99–109.


  1. Osgood ML, 2021, Aneurysmal subarachnoid hemorrhage: Review of the pathophysiology and management strategies. Curr Neurol Neurosci Rep, 21: 50.


  1. Boling B, Groves TR, 2019, Management of subarachnoid hemorrhage. Crit Care Nurse, 39: 58–67.


  1. D’Souza S, 2015, Aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol, 27: 222–240.


  1. Sorrentino ZA, Laurent D, Hernandez J, et al., 2022, Headache persisting after aneurysmal subarachnoid hemorrhage: A narrative review of pathophysiology and therapeutic strategies. Headache, 62: 1120–1132.


  1. Towner JE, Rahmani R, Zammit CG, et al., 2020, Mechanical ventilation in aneurysmal subarachnoid hemorrhage: Systematic review and recommendations. Crit Care, 24: 575.


  1. Voldby B, 1988, Pathophysiology of subarachnoid haemorrhage. Experimental and clinical data. Acta Neurochir Suppl (Wien), 45: 1–6.


  1. van Lieshout JH, Dibué-Adjei M, Cornelius JF, et al., 2018, An introduction to the pathophysiology of aneurysmal subarachnoid hemorrhage. Neurosurg Rev, 41: 917–930.


  1. Hayman LA, Pagani JJ, Kirkpatrick JB, et al., 1989, Pathophysiology of acute intracerebral and subarachnoid hemorrhage: Applications to MR imaging. AJR Am J Roentgenol, 153: 135–139.


  1. De Marchis GM, Pugin D, Meyers E, et al., 2016, Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome. Neurology, 86: 253–260.


  1. Hara H, Edvinsson L, 1987, Perivascular innervation of the cerebral circulation: Involvement in the pathophysiology of subarachnoid hemorrhage. Neurosurg Rev, 10: 171–179.


  1. Etminan N, 2015, Aneurysmal subarachnoid hemorrhage-- status quo and perspective. Transl Stroke Res, 6: 167–170.


  1. Reinhardt MR, 2010, Subarachnoid hemorrhage. J Emerg Nurs, 36: 327–329.


  1. Beighley A, Glynn R, Scullen T, et al., 2021, Aneurysmal subarachnoid hemorrhage during pregnancy: A comprehensive and systematic review of the literature. Neurosurg Rev, 44: 2511–2522.


  1. Seder DB, Mayer SA, 2009, Critical care management of subarachnoid hemorrhage and ischemic stroke. Clin Chest Med, 30: 103–122, vii–ix.


  1. Kellner P, Stoevesandt D, Soukup J, et al., 2012, Aneurysmatisch bedingte Subarachnoidalblutung [Aneurysmal subarachnoid hemorrhage]. Anaesthesist, 61: 792–814.


  1. Cardentey-Pereda AL, Pérez-Falero RA, 2002, Hemorragia subaracnoidea [Subarachnoid hemorrhage]. Rev Neurol, 34: 954–966.


  1. Yamada M, 2015, Cerebral amyloid angiopathy: Emerging concepts. J Stroke, 17: 17–30.


  1. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al., 2015, Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 46: 2032–2060.


  1. Qureshi AI, Mendelow AD, Hanley DF, 2009, Intracerebral haemorrhage. Lancet, 373: 1632–1644.


  1. Sprigg N, Flaherty K, Appleton JP, et al., 2018, Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): An international randomised, placebo-controlled, phase 3 superiority trial. Lancet, 391: 2107–2115.


  1. Feng L, Liang N, Li T, et al., 2020, Efficacy and safety of edaravone for acute intracerebral haemorrhage: Protocol for a systematic review and meta-analysis. BMJ Open, 10: e039366.


  1. Liu H, Uno M, Kitazato KT, et al., 2004, Peripheral oxidative biomarkers constitute a valuable indicator of the severity of oxidative brain damage in acute cerebral infarction. Brain Res, 1025: 43–50.


  1. Abe K, Yuki S, Kogure K, 1988, Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke, 19: 480–485.


  1. Watanabe T, Yuki S, Egawa M, et al., 1994, Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther, 268: 1597–1604.


  1. Mizuno A, Umemura K, Nakashima M, 1998, Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen Pharmacol, 30: 575–578.


  1. Uno M, Kitazato KT, Suzue A, et al., 2005, Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction. Free Radic Biol Med, 39: 1109–1116.


  1. Edaravone Acute Infarction Study Group, 2003, Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 15: 222–229.


  1. Shinohara Y, Yanagihara T, Abe K, et al., 2011, Cerebral infarction/transient ischemic attack (TIA). J Stroke Cerebrovasc Dis, 20: S31–S73. Erratum in: J Stroke Cerebrovasc Dis, 2012;21:428.


  1. Hersh EH, Gologorsky Y, Chartrain AG, et al., 2018, Minimally invasive surgery for intracerebral hemorrhage. Curr Neurol Neurosci Rep, 18: 34.


  1. Wang WZ, Jiang B, Liu HM, et al., 2009, Minimally invasive craniopuncture therapy vs. Conservative treatment for spontaneous intracerebral hemorrhage: Results from a randomized clinical trial in China. Int J Stroke, 4: 11–16.


  1. Sacco S, Marini C, Toni D, et al., 2009, Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke, 40: 394–399.


  1. Babi MA, James ML, 2017, Spontaneous intracerebral hemorrhage: Should we operate? Front Neurol, 8: 645.


  1. Mendelow AD, Gregson BA, Fernandes HM, et al., 2005, Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): A randomised trial. Lancet, 365: 387–397.


  1. Morgan T, Zuccarello M, Narayan R, et al., 2008, Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl, 105: 147–151.


  1. Auer LM, Deinsberger W, Niederkorn K, et al., 1989, Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: A randomized study. J Neurosurg, 70: 530–535.


  1. Ahmed SI, Javed G, Bareeqa SB, et al., 2019, Endovascular coiling versus neurosurgical clipping for aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis. Cureus, 11: e4320.


  1. Marani W, Mannará F, Noda K, et al., 2021, Management of an uncommon complication: anterior choroidal artery occlusion by posterior clinoid process detected through intraoperative monitoring after clipping of paraclinoid aneurysm: 2-Dimensional operative video. Oper Neurosurg (Hagerstown), 21: E124–E125.


  1. Montemurro N, Benet A, Lawton MT, 2016, Clipping of ruptured residual anterior communicating artery aneurysm after endovascular coiling: 3-dimensional operative video. Oper Neurosurg (Hagerstown), 12: 93–94.


  1. Liang B, Zhang Y, Nguyen AV, et al., 2022, Surgical evacuation of intracerebral hemorrhage using DTT-guided parafascicular Brain Path/Myriad technique. Brain Hemorrhages, 3: 120–123.


  1. Zhang L, Mao L, Wang H, 2022, The neuroprotection effects of exosome in central nervous system injuries: A new target for therapeutic intervention. Mol Neurobiol, 59: 7152–7169.


  1. Zhao H, Li Y, Chen L, et al., 2019, HucMSCs-derived miR- 206-knockdown exosomes contribute to neuroprotection in subarachnoid hemorrhage induced early brain injury by targeting BDNF. Neuroscience, 417: 11–23.


  1. Wang Y, Zhang L, Lv L, et al., 2023, Dendritic cell-derived exosomal miR-3064-5p inhibits SIRT6/PCSK9 to protect the blood-brain barrier after subarachnoid hemorrhage. J Biochem Mol Toxicol, 37: e23346.


  1. Cao Y, Li Y, He C, et al., 2021, Selective ferroptosis inhibitor liproxstatin-1 attenuates neurological deficits and neuroinflammation after subarachnoid hemorrhage. Neurosci Bull, 37: 535–549.


  1. Chen J, Wang Y, Li M, et al., 2023, Netrin-1 Alleviates early brain injury by regulating ferroptosis via the PPARγ/ Nrf2/GPX4 signaling pathway following subarachnoid hemorrhage. Transl Stroke Res.


  1. Wang H, Zhou Y, Zhao M, et al., 2023, Ferrostatin-1 attenuates brain injury in animal model of subarachnoid hemorrhage via phospholipase A2 activity of PRDX6. Neuroreport, 34: 606–616.


  1. Gatti S, Lonati C, Acerbi F, et al., 2012, Protective action of NDP-MSH in experimental subarachnoid hemorrhage. Exp Neurol, 234: 230–238.


  1. Fu S, Luo X, Wu X, et al., 2020, Activation of the melanocortin-1 receptor by NDP-MSH attenuates oxidative stress and neuronal apoptosis through PI3K/Akt/Nrf2 pathway after intracerebral hemorrhage in mice. Oxid Med Cell Longev, 2020: 8864100.


  1. Carniglia L, Ramírez D, Durand D, et al., 2016, [Nle4, D-Phe7]-α-MSH inhibits toll-like receptor (TLR)2- and TLR4-induced microglial activation and promotes a M2-like phenotype. PLoS One, 11: e0158564.


  1. Li Y, Sun F, Jing Z, et al., 2017, Glycyrrhizic acid exerts anti-inflammatory effect to improve cerebral vasospasm secondary to subarachnoid hemorrhage in a rat model. Neurol Res, 39: 727–732.


  1. Ieong C, Sun H, Wang Q, et al., 2018, Glycyrrhizin suppresses the expressions of HMGB1 and ameliorates inflammative effect after acute subarachnoid hemorrhage in rat model. J Clin Neurosci, 47: 278–284.


  1. Chang CZ, Wu SC, Kwan AL, 2015, Glycyrrhizin attenuates proinflammatory cytokines through a peroxisome proliferator-activated receptor-γ-dependent mechanism and experimental vasospasm in a rat model. J Vasc Res, 52: 12–21.


  1. Chang CZ, Lin CL, Wu SC, et al., 2014, Purpurogallin, a natural phenol, attenuates high-mobility group box 1 in subarachnoid hemorrhage induced vasospasm in a rat model. Int J Vasc Med, 2014: 254270.


  1. Chang CZ, Wu SC, Kwan AL, et al., 2016, Rhinacanthin-C, A fat-soluble extract from Rhinacanthus nasutus, modulates high-mobility group box 1-related neuro-inflammation and subarachnoid hemorrhage-induced brain apoptosis in a rat model. World Neurosurg, 86: 349–360.


  1. Haruma J, Teshigawara K, Hishikawa T, et al., 2016, Anti-high mobility group box-1 (HMGB1) antibody attenuates delayed cerebral vasospasm and brain injury after subarachnoid hemorrhage in rats. Sci Rep, 6: 37755.


  1. Macdonald RL, Higashida RT, Keller E, et al., 2011, Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: A randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol, 10: 618–625.


  1. Kirkpatrick PJ, Turner CL, Smith C, et al., 2014, Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): A multicentre randomised phase 3 trial. Lancet Neurol, 13: 666–675.


  1. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al., 2007, Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev, 3: CD000277.


  1. Wong GK, Poon WS, Chan MT, et al., 2013, Intracranial pressure monitoring in patients with aneurysmal subarachnoid hemorrhage: A systematic review. Stroke, 44: e38–e40.


  1. Connolly ES Jr., Rabinstein AA, Carhuapoma JR, et al., 2012, Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 43: 1711–1737.


  1. Treggiari MM, Walder B, Suter PM, et al., 2003, Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg, 98: 978–984.


  1. Messina A, Robba C, Stocchetti N, et al., 2022, Hemodynamic management of acute brain injury caused by cerebrovascular diseases: A survey of the European Society of Intensive Care Medicine. Intensive Care Med Exp, 10: 14.


  1. Washington CW, Derdeyn CP, Dhar R, et al., 2016, A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg, 124: 318–327.


  1. Crowley RW, Medel R, Dumont AS, et al., 2011, Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke, 42: 919–923.


  1. Suarez JI, Tarr RW, Selman WR, 2006, Aneurysmal subarachnoid hemorrhage. N Engl J Med, 354: 387–396.


  1. Vergouwen MD, Vermeulen M, Coert BA, et al., 2008, Microthrombosis after aneurysmal subarachnoid hemorrhage: An additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab, 28: 1761–1770.


  1. Frontera JA, Claassen J, Schmidt JM, et al., 2006, Prediction of symptomatic vasospasm after subarachnoid hemorrhage: The modified Fisher scale. Neurosurgery, 59: 21–27.


  1. Macdonald RL, Kassell NF, Mayer S, et al., 2008, Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): Randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke, 39: 3015–3021.
Conflict of interest
The authors declare that they have no competing interests.
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823 Published by AccScience Publishing